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Abstract
a-dystroglycan (a-DG) is a peripheral membrane protein that is an integral component of the dystrophin-glycoprotein
complex. In an inherited subset of muscular dystrophies known as dystroglycanopathies, a-DG has reduced glycosylation
which results in lower affinity binding to several extracellular matrix proteins including laminins. The glycosylation status of
a-DG is normally assessed by the binding of the a-DG antibody IIH6 to a specific glycan epitope on a-DG involved in laminin
binding. Immunocytochemistry and immunoblotting are two of the most widely used methods to detect the amount of a-
DG glycosylation in muscle. While the interpretation of the presence or absence of the epitope on muscle using these
techniques is straightforward, the assessment of a mild defect can be challenging. In this study, flow cytometry was used to
compare the amount of IIH6-reactive glycans in fibroblasts from dystroglycanopathy patients with defects in genes known
to cause a-DG hypoglycosylation to the amount in fibroblasts from healthy and pathological control subjects. A total of
twenty one dystroglycanopathy patient fibroblasts were assessed, as well as fibroblasts from three healthy controls and
seven pathological controls. Control fibroblasts have clearly detectable amounts of IIH6-reactive glycans, and there is a
significant difference in the amount of this glycosylation, as measured by the mean fluorescence intensity of an antibody
recognising the epitope and the percentage of cells positive for the epitope, between these controls and
dystroglycanopathy patient fibroblasts (p,0.0001 for both). Our results indicate that the amount of a-DG glycosylation
in patient fibroblasts is comparable to that in patient skeletal muscle. This method could complement existing
immunohistochemical assays in skeletal muscle as it is quantitative and simple to perform, and could be used when a
muscle biopsy is not available. This test could also be used to assess the pathogenicity of variants of unknown significance
in genes involved in dystroglycanopathies.
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Introduction
The congenital muscular dystrophies (CMDs) are a heteroge-
neous group of autosomal recessive disorders with varying degrees
of clinical severity, broadly characterised by progressive muscle
degeneration, weakness, and often central nervous system
involvement. The dystroglycanopathies are a subgroup of the
CMDs characterised by aberrant a-dystroglycan (a-DG) glycosyl-
ation. They are caused by mutations in several genes involved in
the glycosylation of a-DG; Protein O-mannosyltransferase [1]
(POMT1; MIM 607423), Protein O-mannosyltransferase 2 [2]
(POMT2; MIM 607439), Protein O-mannose ß-1,2-N-acetylglu-
cosaminyltransferase [3] (POMGNT1; MIM 606822), Fukutin [4]
(FKTN; MIM 607440), Fukutin-related protein [5] (FKRP; MIM
606596), like-acetylglucosaminyltransferase [6] (LARGE; MIM
603590), Dolichyl-phosphate mannosyltransferase 2 [7] (DPM2:
MIM 603564), Dolichyl-phosphate mannosyltransferase 3 [8]
(DPM3; MIM 605951), Dolichol Kinase [9] (DOLK; MIM
610746), Isoprenoid Synthase Domain Containing [10,11,12]
(ISPD; MIM 614631), Glycosyltransferase-like domain containing
2 [13] (GTDC2; MIM 147730), b-1,3-N-acetylgalactosaminyl-
transferase 2 [14] (B3GALNT2; MIM 610194), Transmembrane
protein 5 (TMEM5; MIM 605862) [15], b-1,3-N-acetylglucosa-
minyltransferase 1 (B3GNT1; MIM 605517) [16], GDP-mannose
pyrophosphorylase B (GMPPB) [17], and protein kinase-like
protein SgK196 (SGK196) [18].
Mutations in these genes account for the majority of
dystroglycanopathy patients although not all carry mutations in
any of these genes [10,19,20]. Primary dystroglycanopathy
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affecting the dystroglycan encoding gene (DAG1) itself is very rare
and has only been described in one patient thus far [21]. The most
severe forms of dystroglycanopathy are characterised by structural
brain and ocular involvement, in additional to muscle degener-
ation and include Walker-Warburg syndrome (WWS, OMIM
236670), Muscle-Eye-Brain disease (MEB, OMIM 236670), and
Fukuyama Congenital muscular dystrophy (FCMD, OMIM
253800). Milder forms include limb-girdle muscular dystrophies
(LGMD) with no central nervous system involvement (e.g.
LGMD2I, OMIM 607155) and intermediate forms include
muscular dystrophies with or without intellectual disability such
as congenital muscular dystrophy type 1C (MDC1C, OMIM
606612). This phenotypic classification system is described in more
detail in Godfrey et al, 2011 [22].
In skeletal muscle, dystroglycan is encoded by a single gene and
cleaved into a-DG and b-dystroglycan (b-DG) [23,24], which bind
non-covalently to one another and serve as a transmembrane
linker within the dystrophin-glycoprotein complex (DGC), con-
necting the extracellular matrix (ECM) to dystrophin and the actin
cytoskeleton. This connection is established by a-DG binding to
C-terminal globular laminin-G (LG) domain containing proteins
of the ECM (such as laminin-a2, agrin, perlecan, neurexin,
pikachurin, and Slit [23,25,26,27,28,29]) while b-DG binds to
dystrophin and its homologue utrophin [30]. A specific O-
mannose initiated glycan epitope within the mucin-like region of
a-DG is thought to bind to these LG-domain containing ECM
proteins. The composition of this glycan epitope has not yet been
fully elucidated. The anti-a-DG IIH6 antibody has been found to
recognise this epitope [24,31] and blocks the interaction between
a-DG and laminin-a2 [31]. The antibody has served as a useful
diagnostic tool for the secondary dystroglycanopathies, allowing
the extent of a-DG hypoglycosylation to be assessed by techniques
such as immunohistochemistry and immunoblotting.
a-DG is highly glycosylated in a tissue specific and develop-
mentally regulated way essential for its function [32,33]. The core
peptide is 74 kDa, but on SDS-PAGE gels it appears with an
apparent molecular mass of 156 kDa in skeletal muscle and
120 kDa in brain and peripheral nerve due to extensive
glycosylation in the mucin-like region of the protein [24]. Aberrant
glycosylation of a-DG disrupts its connection with the ECM
proteins described above, leading to weakened structural integrity
of basement membranes in muscle, eye and brain, responsible for
the characteristic pathology observed in these target tissues [34],
although signalling defects could also play a role [34,35].
Dystroglycan has been found to be expressed not only in
muscle, eye and brain, the target organs in dystroglycanopathies,
but also in a number of non-muscle tissues, including the kidney,
liver and epithelia [32,33,36]. In skin, dystroglycan is present at
the epidermal basement membrane zone [36]. In these tissues
dystroglycan may serve as a link between epithelial cells and the
basement membrane [36]. Dystroglycan in skin also binds to LG-
domain containing ECM proteins, although its affinity to
particular ligands is different to that of skeletal muscle dystrogly-
can, and its binding to perlecan is five times stronger than to the
most active laminin fragment a-2LG1-3 [37,38]. Additionally,
laminin-a2 is reported to localise within the cytoplasm of basal
keratinocytes in skin [39], rather than the basement membrane as
is the case with muscle and peripheral nerve. The glycosylation of
a-DG in dermal fibroblasts is also distinct from skeletal muscle and
immunoblot analysis indicates that dermal a-DG appears as a
broad smear with a molecular weight of approximately 120 kDa
[36,40].
In this study flow cytometry was used to assess the amount of
IIH6-reactive glycans in dystroglycanopathy patient fibroblasts.
We demonstrate that patients with a dystroglycanopathy consis-
tently have lower levels of these glycans compared to healthy and
pathological controls, and that the level in patient fibroblasts can
be compared to that in skeletal muscle, despite tissue specific
differences in glycosylation [36]. We suggest that this technique
can be used as an experimental and diagnostic aid as it is
quantitative and capable of detecting minor reductions in a-DG
glycosylation.
Materials and Methods
Ethics Statement
All patient samples were obtained from the MRC CNMD
Biobank London (REC reference number 06/Q0406/33). For all
samples collected by the Biobank after 01/09/2006, written
consent for research has been supplied by all patients or their
parent/guardian if the participant was a child/minor. Skin
biopsies were taken from patients and from adults with no known
neuromuscular disease after obtaining written informed patient
consent. All samples have been supplied to the ethically approved
project on congenital muscular dystrophy [Ethics number 00/
5802, reviewed by the Institutional Ethical Review Board of Great
Ormond Street Hospital in the United Kingdom] anonymised.
Copies of the consent forms are in the patient’s hospital notes.
Subjects and Clinical Features
A total of twenty one dystroglycanopathy patient fibroblasts
were assessed in this study; six with mutations in FKRP, three in
POMGNT1, four in POMT1, two in POMT2, two in ISPD, two in
B3GALNT2, and two in GMPPB. Fibroblasts from three healthy
controls and seven pathological controls were also included in the
study. The dystroglycanopathy patients included in this study
included seven phenotypically LGMD patients, six MEB, two
MDC1C, one with CMD (with no mental retardation), one with
overlapping features of CMD and LGMD (with eye and brain
involvement), and four with overlapping features of MEB and
FCMD.
Skin Biopsy and Fibroblast Culture
Fibroblasts were grown from skin biopsies and cultured in
Dulbecco’s modified Eagles medium (Life Technologies, UK)
supplemented with 20% fetal bovine serum (FBS, PAA, UK), 2%
L-glutamine (Sigma, UK) and 1% penicillin, streptomycin and
neomycin (Sigma, UK). Cells were cultured at 37uC in 5% CO2.
Skeletal Muscle Histology and Immunohistochemistry
Immunohistochemichemical studies were performed as previ-
ously described [41]. Unfixed frozen serial sections (7 mm) were
incubated with primary antibodies for 1 hour followed by three
washes in phosphate buffered saline (PBS) pH 7.2, incubated with
the appropriate biotinylated secondary antibodies for 30 minutes,
and subsequently with streptavidin conjugated to Alexa 594 (Life
technologies, UK) for 15 minutes. The primary antibody used to
assess a-DG glycosylation was mouse monoclonal a-dystroglycan
IIH6 (clone IIH6C4, from Kevin Campbell) [24,31], a-dystrogly-
can VIA4-1 (Merck Millipore, UK). An antibody to b-dystrogly-
can (Leica, UK) was used as a control. Sections were evaluated
using a Leica DMR microscope interfaced to MetaMorph
(Molecular Devices, USA).
Flow Cytometry Analysis of Patient Fibroblasts
The following method was modified from Rojek et al [42]. A
few separate batches of the anti-a-DG antibody IIH6 (Merck
Analysis of a-DG Glycosylation by Flow Cytometry
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Millipore, UK) was used to assess the amount of a-DG
glycosylation in patient fibroblasts. Fibroblasts, below passage 10
whenever possible, were grown until approximately 90% conflu-
ent. Cells were detached using non-enzymatic cell dissociation
solution in PBS (Sigma, UK), centrifuged for three minutes at
500 g, and counted and resuspended in PBS to a final density of
200,000 fibroblasts per millilitre. Cells were fixed with 2%
paraformaldehyde for 10 minutes and washed with PBS supple-
mented with 0.1% FBS, centrifuged at 3,000 g for three minutes
and incubated on ice with the following antibodies: anti-a-DG
IIH6 or anti-a-DG VIA4-I for validation studies (Merck Millipore,
UK) for thirty minutes, anti-mouse biotinylated IgM or IgG
(Vector Labs, USA) for twenty minutes, and streptavidin-PE (BD
Pharmingen, UK) for fifteen minutes. After washing, cells were re-
suspended in 500 ml of PBS and transferred to FACS tubes (BD
Biosciences, UK). Data was acquired using the Cyan ADP
analyser (Beckman Coulter, USA) and analysed using the FlowJo
software (Tree Star, USA). Two separate controls for each
fibroblast population were used; one without any staining to
remove background and another without the primary antibody to
gate the IIH6 or VIA4-1 positive population. A total of 10,000
cells were analysed per experiment. Statistical analysis was
performed using unpaired two-tailed t-tests where p,0.05 was
considered significant. The amount of IIH6-reactive glycans was
assessed by the number of cells producing the glycan epitope (the
percentage of IIH6 positive cells) as well as by the level of IIH6
(the mean fluorescence intensity, or MFI). Additionally, the results
were expressed using an integrated MFI value (iMFI) [43][44],
that combines the MFI of IIH6 and the percentage of IIH6
positive cells, and is defined by the following formula:
iMFI~MFI(P):
where P is the percentage of cells positive for the IIH6 epitope
(table 1).
Results
Antibody Choice and Passage Number for Flow
Cytometry Analysis of a-DG Glycosylation in Fibroblasts
The majority of previous studies on a-DG glycosylation have
relied on using one of the antibodies which recognise the
glycosylated epitopes of a-dystroglycan (namely the commercially
available monoclonal antibodies IIH6 and VIA4-1) [45,46,47].
When assessing the extent of a-DG glycosylation using the
commercially available antibodies, muscle immunohistochemistry
is sensitive to batch-to-batch variation [41] yielding variable
results. This batch variation also results in reduced performance
for some antibodies/batches over others using standard diagnostic
techniques.
For flow cytometry, however, different batches of the commer-
cially available antibody anti-a-DG IIH6 (Merck Millipore, UK)
as well as anti-a-DG VIA4-I (Merck Millipore, UK) yielded
consistent results with non-significant differences in MFI values or
the percentage of cells positive for the IIH6 epitope for all four
fibroblast cell lines tested with multiple antibodies/batches.
Control 1 (C1) was tested with two batches of IIH6 and one
batch of VIA4-1 and the MFI values as well as the percentage of
cells positive showed no significant change regardless of batch or
antibody choice (data not shown). C2, pathological control 1
(PC1), patient 18 (P18), and P19 were also tested with two or more
batches of IIH6 and VIA4-1 and also showed no significant
variation in either of the values when using different primary anti-
a-DG antibodies/batches (data not shown). This may be partially
due to the fact that with this method the cells are detached prior to
analysis, so cell-cell and cell-matrix interactions do not impair
antibody binding to the IIH6 and VIA4-1 glycan epitopes.
In order to assess the effect that different passage number had
on the outcome of the results, we performed a series of relevant
experiments. These showed that when the fibroblasts were tested
at later passages (.passage 10) a reduction in the MFI of IIH6-
reactive glycans was observed in control and patient fibroblast cell
lines. Specifically, the MFI value of C1 at passage 5 and C2 at
passage 6 was significantly (p,0.0001) higher than C1 at passage
10 and C2 at passage 11. An additional DMD pathological control
was also tested at a later passage (14) and had a MFI of 31.3
(n = 3), a significant reduction compared to the DMD cases PC1,
PC2 and PC3 as well as C1, C2, and C3 (when below passage 10)
(p,0.0001 in all cases)(data not shown). It should therefore be
noted that passage number should be strictly standardised for
reproducible and valid results using this method. Our results
indicate that a passage number of ,10 should be used.
Assessment of a-DG Glycosylation in Healthy and
Pathological Control Fibroblasts
To ensure the validity of this technique, fibroblast cell lines from
three healthy controls and seven pathological controls were first
tested (table 1). The pathological controls included 5 fibroblast cell
lines with mutations in the dystrophin gene (DYS, MIM 300377;
PC 1, 2, 3, 4, 5), one fibroblast cell line with a ryanodine receptor
mutation (RYR1, MIM 180901; PC6), and one fibroblast cell line
with a mutation in the a-glucosidase gene (GAA, MIM 232300;
PC7). They were individually screened for the amount of IIH6-
reactive glycans by flow cytometry.
All healthy control fibroblast cell lines and pathological control
cell lines were between 70 and 96.4% positive for IIH6-reactive
glycans (table 1). The healthy control fibroblasts (C1, C2, C3) had
an average MFI value of 85.465.7 and the pathological control
fibroblasts had an average MFI value of 77.064.1 (not signifi-
cantly reduced). Individually, all of the pathological controls had a
non-significant difference in MFI compared to the healthy
controls, with the exception of the Duchenne muscular dystrophy
(DMD) fibroblasts PC2 and PC3. PC2 and PC3 showed a
significant reduction in their level of IIH6-reactive glycans
compared to control fibroblasts with a MFI of 65.4 (p = 0.01)
and 63.3 (p= 0.005), however the percentage of cells positive for
the IIH6 epitope for both patients were not significantly reduced
compared to healthy controls. Additionally, while PC1 had a non-
significant reduction in MFI compared to controls, the cells had a
significantly reduced percentage of cells positive for IIH6
(p = 0.006). The significant reduction in MFI for PC2 and PC3
as well as the percentage of IIH6 positive cells for PC1 may be due
to the fact that dystrophin is expressed at low levels in fibroblast
cultures [48,49], possibly leading to a perturbation in the DGC.
The two Becker muscular dystrophy (BMD) patients tested (PC4,
PC5) had no reduction in MFI or the percentage of cells positive
for the IIH6 epitope, however. DMD patients are clinically and
pathologically distinct from suspected dystroglycanopathy patients,
so this should not limit the diagnostic efficacy of this technique.
The Amount of Glycosylated a-DG in Dystroglycanopathy
Patient Fibroblasts is Consistently Reduced Compared to
Healthy Control Fibroblasts
Fibroblasts from 21 dystroglycanopathy patients were tested for
a-DG glycosylation by flow cytometry (table 1). By skeletal muscle
immunohistochemistry, b-dystroglycan and core a-DG was
normal for all patients and controls studied (data not shown). All
Analysis of a-DG Glycosylation by Flow Cytometry
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patient fibroblasts tested had a significantly reduced percentage of
cells positive for the epitope compared to healthy controls as well
as a significantly reduced MFI, with the exception of the two
LGMD2I patient fibroblasts (P5 and P6, table 1) homozygous for
c.826C.A (p.Leu276Ile) in FKRP.
Flow cytometry of dystroglycanopathy patient fibroblasts
revealed that even severely affected patient fibroblasts (e.g.
MEB/FCMD) have detectable, albeit significantly reduced levels
of a-DG glycosylation. Fibroblasts from patients with MEB,
FCMD, MEB/FCMD-like phenotypes (e.g. P2, P7, P8, P9, P10,
P14, P15, P18, P19, P20) had an average MFI of 31.062.9
(figure 1A), statistically reduced compared to the MFI values of the
healthy controls (C1, C2, C3, 85.465.7, P,0.0001). P7 has a
MEB phenotype (mutations in POMGNT1) and a 76% reduction
in MFI compared to the average MFI value of healthy controls (an
MFI value of 20.5 compared to an average MFI value of 85.4).
Additionally, P7 has a 90.5% reduction in the percentage of IIH6
positive cells compared to healthy controls (8.1% positive
compared to an average of 85.7% positive). She was hypotonic
and weak from birth, and at the age of 16 months had abnormal
eye movements and no head control. Less severely affected patient
fibroblasts (e.g. LGMD, LGMD-like) generally have a less but
nonetheless significant reduction in MFI. Patients with LGMD or
LGMD-like phenotypes with no brain involvement (e.g. P1, P5,
P6, P12, P13, and P16) had an average MFI of 61.5612.1 which is
significantly higher than that of MEB/FCMD patients (p = 0.008,
figure 1A). There was a non-significant difference in the average
percentage of IIH6 positive cells in LGMD and LGMD-like
patient fibroblasts compared to MEB/FCMD patient fibroblasts
(39.169.4 compared to 23.764.9), suggesting that MFI may be a
better outcome measure. P16 has a LGMD phenotype (mutations
in ISPD) and a 55% decrease in MFI and a 60.8% decrease in
IIH6 positive cells compared to healthy controls (an MFI of 38.2
and 33.6% cells positive for IIH6, table 1). P16 is currently 12
years of age and has followed a severe LGMD-like disease course;
she is currently non-ambulant [11]. Previous studies on skeletal
muscle [19] have found that patients with severe dystroglycano-
pathy phenotypes do not always have less a-DG glycosylation than
milder phenotypes when assessed using immunohistochemical
studies on skeletal muscle biopsies, especially for FKRP and FKTN,
although there is a broad correlation for POMT1, POMT2, and
POMGNT1.
Flow Cytometry as a Complementary Diagnostic Method
to Muscle Immunohistochemistry
The IIH6 staining in skeletal muscle of the dystroglycanopathy
patients included in this study either showed normal (or almost
normal), markedly reduced, reduced, or absent a-DG glycosyla-
tion (table 1). In figure 2 the patients have been divided into four
categories based on skeletal muscle immunohistochemistry, as
assessed by the diagnostic team’s routine service. Figure 2
illustrates some of the difficulties and subjectivity in interpreting
the extent of a-DG glycosylation given the variable results of
muscle immunohistochemistry with the anti-a-DG IIH6 antibody.
In fibroblasts there was a decrease in the MFI of IIH6
concomitant with a decrease in the intensity of immunolabelling in
the respective patient skeletal muscle sections (figure 1B), despite
the use of different antibodies for the detection of glycosylated a-
DG and tissue specific differences in glycosylation between skeletal
muscle and fibroblasts [36]. Skeletal muscle sections which were
described as ‘absent’ or ‘markedly reduced’ (table 1) for IIH6
labelling yielded an average MFI value of 30.763.1 (n = 9) and an
average percentage positive for IIH6 of 16.963.7. Sections
described as ‘reduced’ for IIH6 yielded an average MFI value of
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38.364.0 (n = 7) and an average percentage positive for IIH6 of
27.963.9. Finally, sections which were described as ‘normal’ (or
almost normal) yielded an average MFI value of 76.767.0 (n = 5)
and an average percentage positive for IIH6 of 75.1613.4.
Similar to the results of previous studies on skeletal muscle
[19,47] there was no direct correlation between primary gene
defect and the extent of a-DG hypo-glycosylation. P10–P13 all
carry mutations in POMT1, and the extent of the reduction of
glycosylated a-DG on skeletal muscle sections ranged from
‘markedly reduced’ to ‘almost normal’ and the MFI of IIH6 in
patient fibroblasts were between 29.0 and 51.1 (normal control
MFI values were between 77.8 and 96.6). These results highlight
the fact that it is the severity of the individual gene defect that
determines severity of phenotype, not necessarily the gene
primarily involved.
Discussion
The dystroglycanopathies encompass a wide range of clinical
severities and variable levels of a-DG glycosylation defects. An
ideal technique to assess patients (or animal models) affected by
these conditions should ideally allow the detection of even mild
reductions in a-DG glycosylation. This can be difficult to establish
with the currently available methods. In this study we show that
flow cytometry is suited for this task, as it allows us to
quantitatively determine the extent of a-DG glycosylation in
normal and dystroglycanopathy patient fibroblasts. Recent studies
have also used flow cytometry as a complementary diagnostic
technique for other proteins in which a deficiency causes muscular
dystrophy. In the study by Kim et al [50], flow cytometry was used
to quantitatively determine the amount of collagen VI expression
in fibroblasts from patients with collagen VI myopathies.
The sensitivity of flow cytometry allows the detection of slight
reductions in the level of IIH6 reactive glycans, which may be
equivocal by immunohistochemistry. The skeletal muscle biopsy of
P13 (figure 2) showed normal or almost normal levels of IIH6
reactive glycans as compared to control skeletal muscle. It was
therefore difficult to determine whether this was a dystroglycano-
pathy case or not based on the results of the muscle pathology
assessment alone. Flow cytometry of P13’s fibroblasts gave an MFI
value of 49.3 with 22.1% positive for IIH6 reactive glycans, both
significantly reduced compared to healthy controls (p = 0.0001 and
p,0.0001, respectively). Sanger sequencing eventually revealed
that this patient has mutations in POMT1. If flow cytometry had
Figure 1. Comparison of the mean fluorescence intensity (MFI) of a-DG glycosylation in patient fibroblasts to respective patient
phenotypic severity and skeletal muscle a-DG IIH6 immunolabelling. (A) Fibroblasts from patients with relatively mild phenotypes (LGMD,
LGMD-like without brain involvement, includes P1, P5, P6, P12, P13, and P16 from table 1) have a significantly (p = 0.008) higher average MFI value
(61.5612.1) than fibroblasts from patients with more severe dystroglycanopathy phenotypes (MEB, FCMD, MEB/FCMD-like, includes P2, P7, P8, P9,
P10, P14, P15, P18, P19, P20 with an MFI average of 31.062.9). (B) In patient fibroblasts, a decrease in the MFI of IIH6 obtained by flow cytometry
concomitant with a decrease in the intensity of immunolabelling in skeletal muscle sections was observed. Skeletal muscle sections which were
described as ‘absent’ or ‘markedly reduced’ (table 1) for IIH6 yielded an average MFI from the respective fibroblasts of 30.763.1 (n = 9). Sections
described as ‘reduced’ for IIH6 yielded an average MFI value of 38.364.0 (n = 7) from the respective fibroblasts. Finally, sections which were described
as ‘normal’ (or almost normal) yielded MFI values of 76.767.7 (n = 5) from the respective fibroblasts. There is a significant difference in the MFI
between both groups reduced for skeletal muscle a-DG IIH6 immunolabelling and the group described as normal or almost normal (p,0.0001 for
absent/markedly reduced, p = 0.0007 for reduced). *** = p,0.001, ** = p,0.01 (unpaired t-test). In all cases values are described as mean fluorescence
intensity 6 standard error of the mean (SEM).
doi:10.1371/journal.pone.0068958.g001
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been used alongside immunohistochemistry, it would have
immediately revealed that P13 was likely a dystroglycanopathy
case.
The integrated MFI or iMFI was included in table 1 to
represent the total amount of IIH6 detected in fibroblasts by flow
cytometry by incorporating both the percentage of IIH6 positive
cells and the MFI of those positive cells into a single, more sensitive
outcome measure [43][44]. While integrating both values into a
single iMFI value does not give the same information as having
both values individually, it provides a useful estimation of the total
amount of IIH6. P17’s skeletal muscle was found to be completely
absent for the IIH6 epitope by immunohistochemistry. The MFI
of this patient, however, was only approximately 42% reduced
compared to healthy controls (an MFI of 48.9 and 85.4,
respectively) while the iMFI was almost 97% reduced (an iMFI
of 385.6 and 7196, respectively). The iMFI therefore better
corresponds to the marked reduction observed in P17’s skeletal
muscle immunohistochemistry. This was similarly the case for P2,
P12, P14, and P16. Additionally, in some cases iMFI better
distinguishes dystroglycanopathy patients who are slightly reduced
for IIH6 from pathological controls (table 1). There is a 29.2%
reduction in MFI between PC1 and P1 (75.6 and 53.1,
respectively) but a 53.4% reduction in iMFI between the two
(5062 and 2361, respectively). Similar results were also observed
for P8, P11, P13, P15, and P17. Based on these data, iMFI is
better able to separate patients with mild reductions in IIH6 from
pathological controls than MFI alone, and better correlates with
immunohistochemical data.
This flow cytometry method can also be used as a tool to
determine whether a patient has a dystroglycanopathy phenotype
when a confirmed genetic diagnosis is not yet available. For
example, when P18 and P19 with mutations in B3GALNT2 and
P20 and P21 with mutations in GMPPB were first analysed by flow
cytometry, variants in these genes had not yet been identified as
the cause of a dystroglycanopathy. In all four patient’s fibroblasts,
flow cytometry revealed a reduction in the MFI of IIH6 and the
percentage of cells positive for the epitope and this was
comparable to the amount detected by skeletal muscle immuno-
histochemistry [14,17]. Our group subsequently confirmed that
Figure 2. Skeletal muscle immunohistochemistry from patients with dystroglycanopathy mutations. Skeletal muscle cryo-sections from
control and dystroglycanopathy patients P1, P2, P9, P12, and P13 immunolabelled with the anti-a-DG IIH6 antibody. P1 and P2 have mutations in
FKRP, P9 has a mutation in POMGNT1, P12 and P13 have mutations in POMT1. b-dystroglycan and core a-DG was similar to controls for all patients
(data not shown) but the amount of IIH6-reactive glycans varied markedly. In P1 the level of IIH6 reactive glycans was reduced, in P2 absent, in P9 and
P12 markedly reduced, and in P13 normal (or near normal) compared to the healthy control.
doi:10.1371/journal.pone.0068958.g002
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variants in both B3GALNT2 and GMPPB can cause dystroglycano-
pathy.
LGMD2I patients homozygous for the c.826C.A (p.Leu276Ile)
variant in FKRP often have mild skeletal muscle pathology, making
diagnosis based on muscle biopsy alone challenging [51].
Therefore, we hoped that flow cytometry would be sensitive
enough to detect a reduction in the amount of IIH6-reactive
glycans in fibroblasts from these patients. The fibroblasts were
found to not be significantly reduced in the MFI of their IIH6
reactive glycans compared to healthy controls but were signifi-
cantly reduced in the percentage of cells positive for IIH6
(p = 0.0001 for P5 and ,0.0001 for P6, table 1). Both patients
were reduced for VIA4-1 reactivity by skeletal muscle immuno-
histochemistry. More LGMD2I patient fibroblasts with the
homozygous mutation c.826C.A (p.Leu276Ile) would need to
be studied to see if this reduction in the percentage of fibroblasts
positive for IIH6 compared to healthy control fibroblasts is a
consistent finding which could be used to aid diagnosis.
It should be reinforced that a-DG glycosylation is tissue specific
[32,33,36], which may modulate its laminin-binding specificity
[52]. Consequently, the results of this study do not allow us to infer
the level of a-DG glycosylation in muscle directly. Additionally,
there are limitations in interpreting the amount of a-DG
glycosylation based solely on the IIH6 epitope, as other unknown
glycan epitopes on a-DG may also have significance for the
function of this receptor in muscle. Nonetheless, we were able to
demonstrate that patients with reduced IIH6 immunolabelling on
skeletal muscle sections also had similarly reduced MFI values for
IIH6 in fibroblasts as assessed by flow cytometry. Larger studies
will be required in order to confirm the precise correlation
between a-DG glycosylation on fibroblasts with skeletal muscle
immunohistochemistry and clinical features. This study neverthe-
less clearly indicates that analysis of dystroglycan glycosylation in
fibroblasts is a useful diagnostic aid for the dystroglycanopathies,
as flow cytometry allows us to detect changes in a-DG
glycosylation. It can also be used to identify possible dystroglyca-
nopathy cases where the muscle immunohistochemistry result is
equivocal or the genetic etiology is not known.
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